Stephens David S., Zimmer Shanta M.
Department of Medicine, Emory University School of Medicine, H-153 Emory University Hospital, 1364 Clifton Road, NE, Atlanta, GA 30322, USA.
Curr Infect Dis Rep. 2002 Oct;4(5):377-386. doi: 10.1007/s11908-002-0004-4.
Neisseria meningitidis (meningococcus), an exclusive pathogen of humans, is the cause of sepsis (meningococcemia) and meningitis, often in otherwise healthy individuals. Several hundred thousand cases of meningococcal disease occur worldwide each year, a number that is frequently accentuated by epidemic outbreaks. In recent years, significant advances, fueled by new molecular approaches and genome sequencing projects, have improved our understanding of the pathogenesis of meningococcal disease and have led to progress in the development of the next generation of meningococcal vaccines. However, the mortality of meningococcal disease remains 10% to 15% for all cases, and is up to 40% in patients with severe sepsis. This review summarizes current knowledge of the pathogenesis, therapy, and prevention of meningococcal disease with emphasis on meningococcal sepsis.
脑膜炎奈瑟菌(脑膜炎球菌)是人类特有的病原体,是败血症(脑膜炎球菌血症)和脑膜炎的病因,通常发生在原本健康的个体中。每年全球有数十万例脑膜炎球菌病病例,这一数字常常因疫情爆发而加剧。近年来,在新的分子方法和基因组测序项目的推动下,取得了重大进展,增进了我们对脑膜炎球菌病发病机制的理解,并在新一代脑膜炎球菌疫苗的研发方面取得了进展。然而,所有病例的脑膜炎球菌病死亡率仍为10%至15%,严重败血症患者的死亡率高达40%。本综述总结了目前关于脑膜炎球菌病发病机制、治疗和预防的知识,重点是脑膜炎球菌败血症。